Literature DB >> 19847891

Hereditary gastrointestinal stromal tumors sharing the KIT Exon 17 germline mutation p.Asp820Tyr develop through different cytogenetic progression pathways.

Isabel Veiga1, Mara Silva, Joana Vieira, Carla Pinto, Manuela Pinheiro, Lurdes Torres, Marta Soares, Lúcio Santos, Hugo Duarte, Artur L Bastos, Camila Coutinho, José Dinis, Carlos Lopes, Manuel R Teixeira.   

Abstract

Hereditary gastrointestinal stromal tumor (GIST) syndrome is a rare autosomal dominant genetic disorder originated by germline mutations in the KIT or PDGFRA genes. We report the third family with hereditary predisposition to GIST due to the KIT Exon 17 germline mutation p.Asp820Tyr and characterize the cytogenetic progression pathways followed by different GIST sharing the same primary genetic event, using a combination of chromosome banding, comparative genomic hybridization (CGH), and fluorescence in situ hybridization (FISH) analyses. The missense mutation p.Asp820Tyr was detected in the proband's rectal and gastric GIST, as well as in his aunt's GIST epiplon metastasis. The mutation p.Asp820Tyr was subsequently also found in the proband's peripheral blood DNA, as well as in that of 4 of 10 relatives thus far analyzed. CGH analysis revealed loss of 14q and 15q in the proband's gastric lesion, whereas FISH analysis of the proband's rectal GIST did not detect loss of 14q and 15q, but instead loss of 4q and 22q and gain of 20q, indicating that the two tumors were independent GIST. Chromosome banding and CGH analyses of the aunt's GIST epiplon metastasis revealed multiple cytogenetic alterations, including 1p loss, but none in common with the two proband's GIST. We conclude that, although the patients share the same KIT Exon 17 germline mutation, the multiple GIST analyzed followed different pathogenetic progression pathways, each of which did not significantly differ from what has been described in sporadic GIST.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19847891     DOI: 10.1002/gcc.20720

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

1.  Significance of Primary Malignant Tumors on the Outcome of Patients With Resected Gastrointestinal Stromal Tumors.

Authors:  Shuzo Kohno; Hiroaki Aoki; Masaichi Ogawa; Kazuhiko Yoshida; Katsuhiko Yanaga
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.

Authors:  S Farag; L E van der Kolk; H H van Boven; A C J van Akkooi; G L Beets; J W Wilmink; N Steeghs
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

3.  Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors.

Authors:  Mara Silva; Isabel Veiga; Franclim R Ribeiro; Joana Vieira; Carla Pinto; Manuela Pinheiro; Bárbara Mesquita; Catarina Santos; Marta Soares; José Dinis; Lúcio Santos; Paula Lopes; Mariana Afonso; Carlos Lopes; Manuel R Teixeira
Journal:  BMC Med       Date:  2010-05-14       Impact factor: 8.775

4.  Characterization of various types of mast cells derived from model mice of familial gastrointestinal stromal tumors with KIT-Asp818Tyr mutation.

Authors:  Noriko Kajimoto; Norihiro Nakai; Mizuka Ohkouchi; Yuka Hashikura; Ning-Ning Liu-Kimura; Koji Isozaki; Seiichi Hirota
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  [Hereditary and non-hereditary syndromic gastointestinal stromal tumours].

Authors:  A Agaimy; A Hartmann
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 6.  Gastrointestinal stromal tumors.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Gastroenterol Clin North Am       Date:  2013-03-13       Impact factor: 3.806

Review 7.  Syndromic gastrointestinal stromal tumors.

Authors:  Riccardo Ricci
Journal:  Hered Cancer Clin Pract       Date:  2016-07-19       Impact factor: 2.857

Review 8.  Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.

Authors:  Hengning Ke; Julhash U Kazi; Hui Zhao; Jianmin Sun
Journal:  Cell Biosci       Date:  2016-10-18       Impact factor: 7.133

9.  Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report.

Authors:  Gulgun Engin; Serpil Eraslan; Hülya Kayserili; Yersu Kapran; Haluk Akman; Ali Akyuz; Nuri Faruk Aykan
Journal:  World J Radiol       Date:  2017-09-28

10.  Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors.

Authors:  Jean-Baptiste Bachet; Jean-François Emile
Journal:  Appl Clin Genet       Date:  2010-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.